Emergent BioSolutions Inc. EBS announced today that it has signed a
license agreement with VaxInnate Corporation under which Emergent acquired the
exclusive right to manufacture and sell VaxInnate's pandemic influenza vaccine
candidate in the United States. The product candidate, a recombinant vaccine,
has the potential to be produced quickly, at high yields and in a
cost-effective manner. This license enables Emergent to fulfill the
requirement to secure a pandemic influenza vaccine candidate under its
contract with the Biomedical Advanced Research and Development Authority
(BARDA), which established Emergent as a Center for Innovation in Advanced
Development and Manufacturing (Center) in June 2012. VaxInnate will continue
to develop its pandemic influenza vaccine candidate under its current BARDA
contract and Emergent will manufacture the pandemic influenza vaccine
candidate using flexible manufacturing technology.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: News
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in